Wegovy

Wegovy. It is a prescription medication approved for chronic weight management in adults with obesity or overweight who have at least one weight-related comorbidity, such as hypertension, type 2 diabetes, or dyslipidemia. The drug is administered via a once-weekly subcutaneous injection and functions as a high-dose formulation of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide. Its development and approval represent a significant advancement in the pharmacotherapy of obesity, a complex chronic disease.

Medical uses

Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management. It is approved for use in adults with a body mass index (BMI) of 30 kg/m² or greater (obesity), or 27 kg/m² or greater (overweight) in the presence of at least one weight-related comorbidity. Clinical studies, such as the STEP clinical trial program, have demonstrated its efficacy in promoting significant and sustained weight loss. The medication is not approved for use in pediatrics or during pregnancy, and its use requires supervision by a healthcare professional like an endocrinologist or primary care physician.

Mechanism of action

The active ingredient, semaglutide, is an analog of human glucagon-like peptide-1 (GLP-1). It acts as a potent agonist at the GLP-1 receptor, which are expressed in multiple organs including the pancreas, brain, and gastrointestinal tract. In the pancreatic islets, it enhances glucose-dependent insulin secretion and suppresses glucagon secretion, aiding blood sugar control. Its primary weight management effects are mediated through actions in the central nervous system, specifically in the hypothalamus, where it reduces appetite and increases feelings of satiety. It also slows gastric emptying, which contributes to reduced food intake.

Adverse effects

The most common adverse reactions are gastrointestinal in nature, including nausea, vomiting, diarrhea, constipation, and abdominal pain. These effects are often dose-dependent and may diminish over time. Serious but less common risks include the potential for acute pancreatitis, gallbladder disease (such as cholelithiasis), acute kidney injury, and increased heart rate. There is a boxed warning regarding the risk of thyroid C-cell tumors observed in rodent studies; its relevance to humans is unknown, and it is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2.

Clinical trials

The efficacy and safety were established primarily through the global STEP clinical trial program, a series of phase 3 trials conducted by Novo Nordisk. Key studies included STEP 1, which demonstrated an average weight loss of nearly 15% in adults with obesity over 68 weeks compared to placebo. Other trials, such as STEP 2 for patients with type 2 diabetes and STEP 3 with intensive behavioral therapy, confirmed significant benefits. These randomized controlled trials were published in journals like The New England Journal of Medicine and presented at conferences like the American Diabetes Association Scientific Sessions.

History and society

Semaglutide was originally developed by the Danish pharmaceutical company Novo Nordisk and first approved for treating type 2 diabetes under the brand name Ozempic. The higher-dose formulation for weight management was approved by the U.S. Food and Drug Administration (FDA) in June 2021. Its approval and subsequent demand have had a substantial impact on public health discussions about obesity, influencing coverage policies by entities like the National Health Service (NHS) and Medicare. The drug's popularity has also sparked widespread media attention and debates on accessibility, cost, and its societal implications for body image and weight stigma. Category:Anti-obesity drugs Category:Glucagon-like peptide-1 receptor agonists